The drug, produced by Pfizer and sold under the brand name Xeljanz, treats arthritis and ulcerative colitis.
The alert is based on data from a post-marketing clinical trial required by the FDA to investigate the drug’s risks compared to other TNF inhibitors. Early data showed that tofacitinib was associated with a higher rate of major adverse cardiovascular events and malignancies than other TNF inhibitors. The study focused on patients ages 50 years and older who have underlying cardiovascular risk factors.
The FDA recommended healthcare professionals weigh the benefits and risks of the drug when prescribing it to patients. The agency also discouraged patients who are prescribed the drug from discontinuing use without first consulting their physician, as doing so could worsen their condition.
More articles on pharmacy:
Avoid painkillers before getting COVID-19 vaccine, experts say
Merck CEO announces retirement
J&J submits FDA application for COVID-19 vaccine
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.